Non-Small Cell Lung Cancer Systemic Therapy

On this page

Quick Reference

RxDrug of choicePembrolizumab 200 mg IV q3w (or 400 mg q6w) plus platinum-doublet chemotherapy for first-line driver-negative metastatic NSCLC; osimertinib 80 mg daily for EGFR-mutant; alectinib 600 mg BID for ALK-positive.

AltAlternativesDurvalumab + tremelimumab + chemotherapy; atezolizumab + bevacizumab + carboplatin + paclitaxel (ABCP) after TKI failure; amivantamab + lazertinib for EGFR; lorlatinib for ALK.

⊘AvoidHigh-dose RT (74 Gy) in stage III; cetuximab with chemoradiation; cisplatin/pemetrexed for squamous histology; non-dihydropyridine CCBs in HF; immunotherapy in active autoimmune disease or chronic immunosuppression.

DxTest of choiceComprehensive next-generation sequencing (NGS) for driver mutations (EGFR, ALK, ROS1, BRAF, etc.) and PD-L1 immunohistochemistry (22C3 or 28-8 assay).

ScKey scorePD-L1 tumor proportion score (TPS) and ECOG performance status; Lung Immune Prognostic Index (LIPI) for risk stratification.

→When to referRefer to thoracic surgery for resectable disease; radiation oncology for stage III or palliative RT; palliative care for symptom management; infectious disease for PLWH; cardiology for cardiotoxicity monitoring.

Systemic therapy for NSCLC is stage- and biomarker-driven: neoadjuvant chemoimmunotherapy for resectable stage II-III, concurrent chemoradiation + durvalumab for stage III, and pembrolizumab-based chemoimmunotherapy or targeted TKI for metastatic disease. NNT to prevent one death at 5 years with pembrolizumab + chemo is ~12.

Systemic therapy for non-small cell lung cancer (NSCLC) is guided by disease stage, histology, biomarkers (EGFR, ALK, PD-L1), and performance status. This summary covers neoadjuvant/perioperative, adjuvant, concurrent chemoradiation, first-line metastatic, and subsequent-line therapies, with emphasis on chemoimmunotherapy, targeted agents, and toxicity management. Key pearls and tables for rapid bedside reference are included.

Overview and Recommendations

Background

•Systemic therapy for NSCLC is selected according to clinical setting, neoadjuvant/perioperative, adjuvant, concurrent chemoradiation, first-line metastatic, and subsequent-line therapy, each with distinct evidence-based regimens. The paradigm has shifted from chemotherapy alone to chemoimmunotherapy and targeted therapy, driven by landmark trials such as KEYNOTE-189, KEYNOTE-407, and PACIFIC.
•Neoadjuvant or perioperative chemoimmunotherapy (e.g., tislelizumab plus platinum-doublet) is now the preferred approach for resectable stage II-III NSCLC, with a pooled analysis showing a 35% reduction in the risk of death (HR 0.65) and significant improvements in major pathological response (risk ratio 3.42) and complete pathological response (risk ratio 5.52) compared with chemotherapy alone.
•For unresectable stage III NSCLC, concurrent chemoradiotherapy (cCRT) with a platinum doublet and 60 Gy thoracic radiotherapy, followed by consolidation durvalumab for 12 months, is the standard of care. The PACIFIC trial demonstrated a 5-year overall survival of 42.9% with durvalumab versus 33.4% with placebo (HR 0.72).
•In metastatic NSCLC, the presence of actionable driver alterations (EGFR, ALK, ROS1, BRAF V600E, NTRK, MET, RET, HER2) dictates first-line targeted therapy. For patients without such alterations, PD-L1 tumor proportion score (TPS) guides immunotherapy use: pembrolizumab monotherapy for TPS ≥50% (5-year OS 31.9% vs 16.3%; NNT=6) or pembrolizumab plus platinum-doublet chemotherapy for all PD-L1 levels (5-year OS ~19% vs ~11%; NNT=12).
•The four pillars of first-line therapy for driver-negative metastatic NSCLC, pembrolizumab, platinum, pemetrexed (nonsquamous) or paclitaxel (squamous), replaced the legacy chemotherapy-only approach following KEYNOTE-189 (2018) and KEYNOTE-407 (2018). Combined relative mortality reduction approaches 40% compared with chemotherapy alone.
•Subsequent-line therapy after progression on first-line chemoimmunotherapy or targeted therapy includes single-agent docetaxel, ramucirumab plus docetaxel, or, for EGFR-mutant disease after TKI failure, chemotherapy plus antiangiogenic agent plus immune checkpoint inhibitor (e.g., atezolizumab + bevacizumab + carboplatin + paclitaxel [ABCP]) or amivantamab plus chemotherapy.

Evaluation

•Suspect the need for systemic therapy in any patient with newly diagnosed NSCLC after complete staging (CT chest/abdomen, PET-CT, brain MRI). Determine the clinical setting: resectable (stage I-IIIA), unresectable stage III, or metastatic (stage IV).
•Assess performance status using the ECOG scale. For neoadjuvant or concurrent chemoradiation, ECOG 0-1 is required. For metastatic disease, ECOG 0-2 may be considered for targeted therapy, but immunotherapy-containing regimens are typically reserved for ECOG 0-1.
•Obtain histologic subtype (nonsquamous vs squamous) from biopsy. This determines the chemotherapy backbone: pemetrexed for nonsquamous, paclitaxel/nab-paclitaxel for squamous.
•Order mandatory biomarker testing: EGFR mutations, ALK rearrangements, and PD-L1 TPS (by immunohistochemistry). For nonsquamous histology, also test for ROS1, BRAF V600E, NTRK, MET exon 14 skipping, RET, and HER2. For squamous, consider PD-L1 and possibly NGS if young or never-smoker.
•Evaluate for actionable driver alterations using a comprehensive next-generation sequencing (NGS) panel. If EGFR mutation or ALK rearrangement is detected, first-line therapy is a targeted TKI (osimertinib for EGFR, alectinib or lorlatinib for ALK).
•Assess for brain metastases with MRI brain. In EGFR-mutant or ALK-positive disease, TKIs have high intracranial activity; in driver-negative disease, brain metastases may require local therapy (SRS or WBRT) before or concurrent with systemic therapy.
•Evaluate pulmonary function (spirometry, DLCO) before neoadjuvant therapy or concurrent chemoradiation. Preexisting interstitial lung disease (ILD) is a risk factor for pneumonitis with immunotherapy and chemoradiation.
•Check baseline complete blood count, comprehensive metabolic panel (including renal function and liver enzymes), and thyroid function tests. For patients receiving cisplatin, assess renal function (eGFR >60 mL/min) and consider hydration protocols.
•Assess for contraindications to immunotherapy: active autoimmune disease (except controlled thyroiditis, vitiligo), history of solid organ transplant, active infection (including HIV with low CD4 count), or chronic steroid use >10 mg prednisone daily.
•For patients with resectable stage II-III disease, evaluate surgical candidacy (tumor resectability, pulmonary reserve, comorbidities) before initiating neoadjuvant therapy. Multidisciplinary discussion with thoracic surgery and radiation oncology is essential.
•Consider the Lung Immune Prognostic Index (LIPI) based on pretreatment LDH and derived neutrophil-to-lymphocyte ratio. Poor LIPI is associated with worse outcomes on chemoimmunotherapy (median PFS 3.6 months vs 9.0 months for good/intermediate LIPI).
•Document smoking history, occupational exposures, and family history of lung cancer. These factors may influence risk of toxicity and prognosis.

Management

•For resectable stage II-III NSCLC (ECOG 0-1), initiate neoadjuvant chemoimmunotherapy: tislelizumab 200 mg IV q3w plus platinum-doublet chemotherapy (e.g., carboplatin AUC 5 + pemetrexed 500 mg/m² for nonsquamous, or carboplatin AUC 5 + paclitaxel 175 mg/m² for squamous) for 3-4 cycles. Follow with surgery within 4-6 weeks of last dose.
•After surgery, continue adjuvant immunotherapy: tislelizumab 200 mg IV q3w for up to 1 year (or atezolizumab 840 mg IV q2w for up to 1 year for stage II-IIIA PD-L1 ≥1%). For EGFR-mutant resectable disease, consider neoadjuvant osimertinib 80 mg daily with or without chemotherapy, then adjuvant osimertinib.
•For unresectable stage III NSCLC (ECOG 0-1), administer concurrent chemoradiotherapy: thoracic radiotherapy 60 Gy in 2 Gy fractions with a platinum doublet. Preferred regimens: cisplatin 75 mg/m² + pemetrexed 500 mg/m² q3w for nonsquamous; cisplatin 50 mg/m² + etoposide 50 mg/m² q4w or carboplatin AUC 2 + paclitaxel 45 mg/m² weekly for squamous.
•After cCRT, if no progression, start consolidation durvalumab 10 mg/kg IV q2w for 12 months. For EGFR-mutant disease, use osimertinib 80 mg daily instead of durvalumab. Do not use high-dose RT (74 Gy) or add cetuximab, both worsen outcomes.
•For first-line metastatic NSCLC with sensitizing EGFR mutation, initiate osimertinib 80 mg orally once daily. Alternative: amivantamab 1050 mg IV (for <80 kg) or 1400 mg IV (≥80 kg) plus lazertinib 240 mg orally once daily, which showed superior PFS vs osimertinib (HR 0.70).
•For first-line ALK-positive NSCLC, start alectinib 600 mg orally twice daily (HR 0.43 vs crizotinib) or lorlatinib 100 mg orally once daily (HR 0.19; 5-year PFS 60%). Monitor for bradycardia, hyperlipidemia, and CNS effects.
•For first-line driver-negative metastatic NSCLC with PD-L1 TPS ≥50%, offer pembrolizumab monotherapy 200 mg IV q3w (or 400 mg q6w) for up to 2 years. For PD-L1 TPS 1-49% or any PD-L1, use pembrolizumab 200 mg IV q3w plus platinum-doublet chemotherapy: for nonsquamous, pemetrexed 500 mg/m² + cisplatin 75 mg/m² or carboplatin AUC 5 q3w for 4 cycles, then maintenance pembrolizumab + pemetrexed; for squamous, carboplatin AUC 5 + paclitaxel 175 mg/m² or nab-paclitaxel 100 mg/m² weekly for 4 cycles, then pembrolizumab alone.
•Alternative first-line chemoimmunotherapy: durvalumab 1500 mg IV q3w plus tremelimumab 75 mg IV q3w (up to 4 doses) plus platinum-doublet chemotherapy for up to 4 cycles, then durvalumab maintenance. This regimen improved OS vs chemotherapy alone (HR 0.77).
•For patients with poor performance status (ECOG 2) or contraindications to immunotherapy, consider platinum-doublet chemotherapy alone (e.g., carboplatin AUC 5 + pemetrexed 500 mg/m² q3w for nonsquamous) or single-agent chemotherapy (e.g., docetaxel 75 mg/m² q3w).
•After progression on first-line EGFR TKI, preferred second-line therapy is chemotherapy plus antiangiogenic agent plus immune checkpoint inhibitor: atezolizumab 1200 mg IV q3w + bevacizumab 15 mg/kg IV q3w + carboplatin AUC 5 + paclitaxel 175 mg/m² q3w (ABCP regimen) for 4-6 cycles, then maintenance atezolizumab + bevacizumab. Alternative: amivantamab 1050-1400 mg IV weekly for 4 weeks then q3w plus carboplatin AUC 5 + pemetrexed 500 mg/m².
•After progression on first-line chemoimmunotherapy (driver-negative), second-line options include docetaxel 75 mg/m² IV q3w, ramucirumab 10 mg/kg IV q2w plus docetaxel 75 mg/m², or single-agent pembrolizumab if not previously used and PD-L1 ≥50%. For patients with secondary resistance to immunotherapy and HLA-A2+, consider OSE2101 cancer vaccine (improved OS vs chemotherapy: 11.1 vs 7.5 months).
•Monitor for immune-related adverse events (irAEs) during immunotherapy: check thyroid function, liver enzymes, and creatinine every 3-6 weeks. For grade 2 irAEs, hold immunotherapy and consider corticosteroids (prednisone 0.5-1 mg/kg/day). For grade 3-4 irAEs, discontinue immunotherapy and start high-dose corticosteroids (methylprednisolone 1-2 mg/kg/day).
•Provide supportive care: antiemetics (aprepitant, ondansetron) for chemotherapy; G-CSF for febrile neutropenia prophylaxis if risk >20%; growth factors for anemia; and prompt management of diarrhea, rash, and pneumonitis. For patients on cisplatin, ensure aggressive hydration and monitor renal function.
•Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with heart failure or reduced LVEF. Avoid concurrent use of strong CYP3A4 inhibitors with lorlatinib. Do not use pembrolizumab in patients with active autoimmune disease or on chronic immunosuppression.
•Refer to palliative care early for symptom management, especially in metastatic disease. Refer to radiation oncology for palliative radiotherapy to symptomatic bone metastases or brain metastases. Refer to thoracic surgery for evaluation of oligometastatic disease amenable to local therapy.
•Discharge criteria for outpatient systemic therapy: patient stable, no grade ≥3 toxicity, adequate organ function, and clear plan for next cycle. For inpatient admission: febrile neutropenia, grade 3-4 irAEs, severe dehydration, or respiratory compromise.

Board Review — High Yield

•KEYNOTE-189, Pembrolizumab + pemetrexed/platinum for nonsquamous NSCLC: OS HR 0.60, 5-year OS 19.4% vs 11.3%.
•KEYNOTE-407, Pembrolizumab + carboplatin + paclitaxel for squamous NSCLC: OS HR 0.71, 5-year OS 18.4% vs 9.7%.
•PACIFIC, Consolidation durvalumab after chemoradiation for stage III NSCLC: 5-year OS 42.9% vs 33.4% (HR 0.72).
•RTOG 0617, High-dose RT (74 Gy) is harmful: median OS 20.3 vs 28.7 months with 60 Gy.
•Neoadjuvant chemoimmunotherapy, Pooled HR for OS 0.65; benefit seen even in PD-L1 <1% (HR 0.74).
•Osimertinib, First-line for EGFR-mutant NSCLC; CNS PFS HR 0.17 after CRT.
•Alectinib, First-line for ALK-positive NSCLC: PFS HR 0.43 vs crizotinib.
•ATTLAS, ABCP regimen after TKI failure in EGFR/ALK-mutant NSCLC: PFS HR 0.62.
•IrAEs and outcomes, Any-grade irAEs associated with higher ORR (vs 18.0%) but grade 3-4 irAEs paradoxically linked to worse OS.
•Performance status, ECOG PS is the strongest predictor of OS in first-line immunotherapy; only ECOG 0-1 for chemoimmunotherapy.

Deep Dive — Evidence Details

Setting-Based Framework

▸Neoadjuvant/perioperative chemoimmunotherapy improves OS vs neoadjuvant chemo alone (HR 0.65) [7]
▸First-line metastatic therapy: targeted for driver mutations, chemoimmunotherapy for driver-negative

HY High Yield: Neoadjuvant/perioperative approach preferred over adjuvant for resectable stage II-III NSCLC [7]

Systemic therapy for (NSCLC) is selected by disease stage, resectability, performance status, and biomarkers. Neoadjuvant/perioperative chemoimmunotherapy is preferred for resectable stage II-III NSCLC, improving event-free survival (HR 0.58) and overall survival (HR 0.65) ^[7]^A1a^[17]^A1a. Adjuvant immunotherapy after chemotherapy is an option, but neoadjuvant approaches appear more effective ^[7]^A1a^[12]^A1b. First-line metastatic therapy depends on biomarker status: osimertinib for EGFR, alectinib or lorlatinib for ALK ^[10]^A1b^[13]^A1b^[19]^A1b. For driver-negative tumors, pembrolizumab plus platinum-doublet chemotherapy is standard (KEYNOTE-189 OS HR 0.60; KEYNOTE-407 OS HR 0.71) ^[18]^A1b^[20]^A1b. After progression on EGFR-TKIs, chemotherapy plus anti-angiogenic and immune checkpoint inhibitor is optimal ^[8]^A1a. A key controversy: neoadjuvant/perioperative immunotherapy is superior to adjuvant (OS HR 0.65 vs 0.91) ^[7]^A1a. Pearl: When selecting systemic therapy for NSCLC, the first decision point is the clinical setting, neoadjuvant/perioperative chemoimmunotherapy should be the default for resectable stage II-III disease, while first-line metastatic therapy is driven by biomarkers and histology, with pembrolizumab-based chemoimmunotherapy the backbone for driver-negative tumors.

Key Trials by Setting

Setting	Key Trial	Regimen	Outcome
Neoadjuvant/perioperative	CheckMate 816, KEYNOTE-671, etc. (meta-analysis ^[7]^A1a)	Chemoimmunotherapy	EFS HR 0.58, OS HR 0.65
Adjuvant	IMpower010 ^[12]^A1b	Atezolizumab after chemo	DFS improved; OS HR 0.43 (PD-L1≥50%)
First-line EGFR-mutant	MARIPOSA ^[13]^A1b	Amivantamab + lazertinib vs osimertinib	PFS HR 0.70
First-line ALK-positive	ALEX ^[10]^A1b^[16]^A1b	Alectinib vs crizotinib	PFS HR 0.43; OS HR 0.78
First-line ALK-positive	CROWN ^[19]^A1b	Lorlatinib vs crizotinib	PFS HR 0.19; 5-yr PFS 60%
First-line nonsquamous	KEYNOTE-189 ^[18]^A1b	Pembrolizumab + chemo	OS HR 0.60; 5-yr OS 19.4%
First-line squamous	KEYNOTE-407 ^[20]^A1b	Pembrolizumab + chemo	OS HR 0.71; 5-yr OS 18.4%
Subsequent-line (EGFR-mutant)	Network meta-analysis ^[5]^A1a	Amivantamab + chemo or ICI + antiangio + chemo	PFS HR 0.48 and 0.51 vs chemo

Concurrent Chemotherapy with RT

▸cCRT with 60 Gy RT is standard; 74 Gy harmful [29][39]
▸Consolidation durvalumab improves 5-year OS to 42.9% [25]

! Warning: Do not use high-dose RT (74 Gy) - worsens OS [29][39]

CP Clinical Pearl: Do not add cetuximab - no survival benefit, increased toxicity [39]

For unresectable stage III NSCLC, definitive treatment is concurrent chemoradiotherapy (cCRT) with a platinum doublet and 60 Gy RT (2 Gy fractions) ^[29]^A1b^[39]^A1b. Higher doses (74 Gy) worsen OS (HR 1.38) and must not be used. Before starting, assess ECOG, pulmonary function, stage, histology, and EGFR/ALK status. Preferred regimens: cisplatin/pemetrexed for nonsquamous (lower toxicity than etoposide/cisplatin) ^[34]^A1b; cisplatin/etoposide or carboplatin/paclitaxel for squamous. After cCRT without progression, consolidation durvalumab (10 mg/kg IV q2w for 12 months) improves 5-year OS from 33.4% to 42.9% (HR 0.72) ^[25]^A1b; sugemalimab is an alternative ^[40]^A1b. For EGFR-mutant NSCLC, osimertinib is indicated after CRT (CNS PFS HR 0.17) ^[23]^A1b. Do not add cetuximab (no benefit, increased toxicity) ^[39]^A1b. Monitor weekly CBCs during cCRT; CT chest 1-6 weeks after to confirm no progression. Pearl: For unresectable stage III NSCLC, the winning combination is 60 Gy RT with a platinum doublet, followed by 12 months of consolidation durvalumab, this yields 5-year survival of 42.9% ^[25]^A1b. Adding concurrent immunotherapy or high-dose RT only increases toxicity without benefit.

Concurrent Chemoradiotherapy Regimens in Pivotal Trials

Regimen	Dose	Schedule	Histology	Key Trial
Carboplatin/paclitaxel	Carboplatin AUC 2, paclitaxel 45 mg/m²	Weekly during RT	Squamous or nonsquamous	RTOG 0617 ^[39]^A1b
Cisplatin/pemetrexed	Cisplatin 75 mg/m², pemetrexed 500 mg/m²	q3w × 3 cycles with RT	Nonsquamous	PROCLAIM ^[34]^A1b
Cisplatin/etoposide	Cisplatin 50 mg/m², etoposide 50 mg/m²	q4w × 2 cycles with RT	Squamous	PROCLAIM ^[34]^A1b

Targeted and Immune Therapy

▸Pembrolizumab monotherapy for PD-L1 ≥50%: NNT=6 for 5-year OS [26]
▸After EGFR-TKI failure, ABCP or amivantamab + chemo preferred [5][50]

HY High Yield: Subcutaneous pembrolizumab 790 mg q6w is noninferior to IV [11]

Biomarker stratification (EGFR, ALK, PD-L1 TPS) guides first-line therapy. For PD-L1 TPS ≥50%, pembrolizumab monotherapy yields 5-year OS 31.9% vs 16.3% (HR 0.63, NNT=6) ^[26]^A1b^[55]^A1b. For PD-L1 ≥1%, combination chemoimmunotherapy is preferred (KEYNOTE-189: OS HR 0.56; KEYNOTE-407: OS HR 0.71) ^[15]^A1b^[18]^A1b^[20]^A1b. Subcutaneous pembrolizumab (790 mg q6w) is noninferior ^[11]^A1b. Adjuvant pembrolizumab for stage IB-IIIA improves DFS (HR 0.76) ^[59]^A1b. After EGFR-TKI failure, ABCP (atezolizumab + bevacizumab + paclitaxel + carboplatin) improves PFS (HR 0.62), especially in PD-L1 ≥50% (HR 0.24) ^[50]^A1b; pembrolizumab plus chemotherapy did not show benefit in KEYNOTE-789 ^[27]^A1b. Bevacizumab + chemo improves intracranial PFS in brain metastases (HR 0.49) ^[58]^A1b. Emerging: izalontamab brengitecan (EGFR-HER3 ADC) shows 47.4% ORR in heavily pretreated EGFR-mutated NSCLC ^[56]^A1a; OSE2101 vaccine improves OS vs chemo in HLA-A2+ patients with secondary resistance to ICI (HR 0.59) ^[42]^A1b. Real-world outcomes are shorter than trials ^[57]^A1b. Monitor for immune-related AEs (pneumonitis, colitis, hepatitis) and manage promptly. Pearl: For first-line therapy in metastatic NSCLC without driver mutations, pembrolizumab plus platinum-doublet chemotherapy provides a consistent OS benefit across PD-L1 levels, with an NNT of approximately 11-12 to prevent one death at 5 years; monotherapy remains an option for PD-L1 TPS ≥50% (NNT = 6).

Key First-Line Immunotherapy Trials in Metastatic NSCLC

Trial	Population	Regimen	OS HR (95% CI)	5-Year OS (Experimental vs Control)	NNT for 5-Year OS
KEYNOTE-024 ^[26]^A1b^[55]^A1b	PD-L1 TPS ≥50%	Pembrolizumab monotherapy	0.63 (0.47-0.86)	31.9% vs 16.3%	6
KEYNOTE-189 ^[15]^A1b^[18]^A1b	Nonsquamous, all PD-L1	Pembrolizumab + pemetrexed-platinum	0.56 (0.46-0.69)	19.4% vs 11.3%	12
KEYNOTE-407 ^[20]^A1b	Squamous, all PD-L1	Pembrolizumab + carboplatin + (nab-)paclitaxel	0.71 (0.59-0.85)	18.4% vs 9.7%	11

Toxicity and Supportive Care

▸Any-grade irAEs predict better outcomes, but grade 3-4 irAEs worsen OS [70]
▸Pneumonitis risk increased with preexisting interstitial lung disease or prior chest RT [61]

! Warning: Grade 3-4 irAEs paradoxically associated with worse OS despite higher ORR [70]

Systemic therapy toxicities vary by class. Platinum-based chemoradiation: acute esophageal grade 3-4 in 18% (vs 4% sequential) ^[65]^A1a. Pembrolizumab monotherapy: grade 3-5 TRAEs 31.2% ^[26]^A1b. Immune-related AEs (irAEs): CTLA-4 agents cause more colitis, hypophysitis, rash; PD-1/PD-L1 agents cause more pneumonitis, hypothyroidism, arthralgia ^[62]^B2a. Pneumonitis occurs in 2-5% with ICI; risk factors: preexisting interstitial abnormalities (HR 8.91) and prior chest radiation (HR 2.81) ^[61]^B3b. Grade 3-4 pneumonitis worsens OS. Combination chemoimmunotherapy increases immune-mediated AEs but no unexpected toxicities ^[72]^A1a. Neoadjuvant chemoimmunotherapy: grade 3-4 TRAE risk difference 3.42%, slight increase in surgery cancellation ^[71]^A1a. Development of any-grade irAEs is associated with higher ORR (41.49% vs 18.01%) and longer OS (HR 0.40), but grade 3-4 irAEs correlate with worse OS ^[70]^C4. Supportive care: prompt recognition, grading, treatment interruption, and early corticosteroid use. Thyroid function monitoring recommended. Pearl: The development of any-grade immune-related adverse events during PD-1/PD-L1 therapy is associated with a 2.3-fold higher objective response rate in lung cancer, but severe (grade 3-4) irAEs paradoxically correlate with worse overall survival, necessitating vigilant monitoring and early corticosteroid use ^[70]^C4.

Distinct irAE Profiles of CTLA-4 vs PD-1/PD-L1 Inhibitors

irAE	CTLA-4 vs PD-1 (Odds Ratio)	95% CI	More Frequent Class
Colitis (all grades)	8.7	5.8-12.9	CTLA-4
Hypophysitis (all grades)	6.5	3.0-14.3	CTLA-4
Rash (all grades)	2.0	1.8-2.3	CTLA-4
Pneumonitis (all grades)	6.4	3.2-12.7	PD-1
Hypothyroidism (all grades)	4.3	2.9-6.3	PD-1
Arthralgia (all grades)	3.5	2.6-4.8	PD-1
Vitiligo (all grades)	3.5	2.3-5.3	PD-1
Grade 3/4 irAEs (any)	31% vs 10%	-	CTLA-4

Data from 48 trials, 6938 patients ^[62]^B2a

References

[1]
Riely GJ, Wood DE, Ettinger DS et al.. “Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38754467 ↗
L1GUIDELINECited in: Setting-Based Framework
[2]
Ettinger DS, Aisner DL, Wood DE et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30006423 ↗
L1GUIDELINECited in: Setting-Based Framework, Chemotherapy Regimens
[3]
Ettinger DS, Wood DE, Aisner DL et al.. “NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37015337 ↗
L1GUIDELINECited in: Setting-Based Framework
[4]
Ettinger DS, Wood DE, Akerley W et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 26957612 ↗
L1GUIDELINECited in: Setting-Based Framework, Targeted and Immune Therapy, Toxicity and Supportive Care
[5]
Pang LL, Zhuang WT, Chen ZH et al.. “Chemotherapy-Based Combination Regimens for Advanced EGFR-Mutant NSCLC After EGFR-TKI Failure: A Network Meta-Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40081325 ↗
L1SR_MA_RCTCited in: Setting-Based Framework, Chemotherapy Regimens
[6]
Passaro A, Leighl N, Blackhall F et al.. “ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35176458 ↗
L1GUIDELINECited in: Setting-Based Framework
[7]
Rossi G, Barcellini L, Tagliamento M et al.. “Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses.” ESMO open (2025). PMID: 40913837 ↗
L1SR_MA_RCTCited in: Setting-Based Framework
[8]
Zhao Y, He Y, Wang W et al.. “Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.” The Lancet. Oncology (2024). PMID: 39159630 ↗
L1SR_MA_RCTCited in: Setting-Based Framework
[9]
Conforti F, Pala L, Bagnardi V et al.. “Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29778737 ↗
L1SR_MA_RCTCited in: Setting-Based Framework
[10]
Mok T, Camidge DR, Gadgeel SM et al.. “Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32418886 ↗
L1RCTCited in: Setting-Based Framework
[11]
Felip E, Rojas CI, Schenker M et al.. “Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40157574 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
[12]
Felip E, Altorki N, Zhou C et al.. “Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37467930 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens
[13]
Felip E, Cho BC, Gutiérrez V et al.. “Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38942080 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens
[14]
Burotto M, Zvirbule Z, Mochalova A et al.. “IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37268157 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Toxicity and Supportive Care
[15]
Rodríguez-Abreu D, Powell SF, Hochmair MJ et al.. “Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33894335 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
[16]
Peters S, Camidge R, Dziadziuszko R et al.. “Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41110693 ↗
L1RCTCited in: Setting-Based Framework
[17]
Sorin M, Prosty C, Ghaleb L et al.. “Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.” JAMA oncology (2024). PMID: 38512301 ↗
L1SR_MA_RCTCited in: Setting-Based Framework
[18]
Garassino MC, Gadgeel S, Speranza G et al.. “Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36809080 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
[19]
Solomon BJ, Liu G, Felip E et al.. “Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38819031 ↗
L1RCTCited in: Setting-Based Framework
[20]
Novello S, Kowalski DM, Luft A et al.. “Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36735893 ↗
L1RCTCited in: Setting-Based Framework, Chemotherapy Regimens, Targeted and Immune Therapy
[21]
Eberhardt WE, De Ruysscher D, Weder W et al.. “2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 25897013 ↗
L1GUIDELINECited in: Concurrent Chemotherapy with RT
[22]
Besse B, Adjei A, Baas P et al.. “2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24669016 ↗
L1GUIDELINECited in: Concurrent Chemotherapy with RT
[23]
Lu S, Ahn MJ, Reungwetwattana T et al.. “Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39289145 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[24]
Belani CP, Chakraborty BC, Modi RI et al.. “A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27831503 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[25]
Spigel DR, Faivre-Finn C, Gray JE et al.. “Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35108059 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Special Populations
[26]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30620668 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Chemotherapy Regimens, Targeted and Immune Therapy, Toxicity and Supportive Care
[27]
Yang JC, Lee DH, Lee JS et al.. “Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39173098 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Targeted and Immune Therapy
[28]
Scagliotti GV, Parikh P, von Pawel J et al.. “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18506025 ↗
L1RCTCited in: Concurrent Chemotherapy with RT, Special Populations
[29]
Bradley JD, Hu C, Komaki RR et al.. “Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31841363 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[30]
Sun H, Li M, Huang W et al.. “Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39374473 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[31]
Miura S, Tanaka H, Misumi T et al.. “Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40239133 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[32]
Bradley JD, Sugawara S, Lee KH et al.. “Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 41082707 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[33]
Kenmotsu H, Yamamoto N, Yamanaka T et al.. “Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32407216 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[34]
Senan S, Brade A, Wang LH et al.. “PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26811519 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[35]
Li Z, Hu J, Chen J et al.. “Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2026). PMID: 42296979 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[36]
Peled N, Tufman A, Sequist LV et al.. “COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.” ESMO open (2025). PMID: 41139117 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[37]
Senan S, Özgüroğlu M, Daniel D et al.. “Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.” ESMO open (2022). PMID: 35247871 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[38]
Watanabe S, Yoshioka H, Sakai H et al.. “Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM.” ESMO open (2024). PMID: 38520847 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[39]
Bradley JD, Paulus R, Komaki R et al.. “Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.” The Lancet. Oncology (2015). PMID: 25601342 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[40]
Zhou Q, Chen M, Jiang O et al.. “Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial.” The Lancet. Oncology (2022). PMID: 35038429 ↗
L1RCTCited in: Concurrent Chemotherapy with RT
[41]
Wang C, Wang W, Liu H et al.. “Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41344593 ↗
L1RCTCited in: Chemotherapy Regimens
[42]
Besse B, Felip E, Garcia Campelo R et al.. “Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37704166 ↗
L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy, Special Populations
[43]
Papadimitrakopoulou VA, Mok TS, Han JY et al.. “Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32861806 ↗
L1RCTCited in: Chemotherapy Regimens
[44]
Leighl NB, Akamatsu H, Lim SM et al.. “Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38857463 ↗
L1RCTCited in: Chemotherapy Regimens
[45]
Brahmer JR, Lee JS, Ciuleanu TE et al.. “Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36223558 ↗
L1RCTCited in: Chemotherapy Regimens
[46]
Johnson ML, Cho BC, Luft A et al.. “Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36327426 ↗
L1RCTCited in: Chemotherapy Regimens
[47]
He J, Tsuboi M, Weder W et al.. “Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40454705 ↗
L1RCTCited in: Chemotherapy Regimens
[48]
Gadgeel S, Rodríguez-Abreu D, Speranza G et al.. “Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32150489 ↗
L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy
[49]
de Castro G, Kudaba I, Wu YL et al.. “Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36306479 ↗
L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy
[50]
Park S, Kim TM, Han JY et al.. “Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37861993 ↗
L1RCTCited in: Chemotherapy Regimens, Targeted and Immune Therapy
[51]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35545176 ↗
L1GUIDELINECited in: Targeted and Immune Therapy
[52]
Ettinger DS, Wood DE, Aisner DL et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33668021 ↗
L1GUIDELINECited in: Targeted and Immune Therapy
[53]
Ettinger DS, Wood DE, Aisner DL et al.. “Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404761 ↗
L1GUIDELINECited in: Targeted and Immune Therapy
[54]
Ettinger DS, Wood DE, Aggarwal C et al.. “NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31805526 ↗
L1GUIDELINECited in: Targeted and Immune Therapy
[55]
Reck M, Rodríguez-Abreu D, Robinson AG et al.. “Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33872070 ↗
L1RCTCited in: Targeted and Immune Therapy
[56]
Hong SD, Wang YS, Zhao HY et al.. “Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41611210 ↗
L1SR_MA_RCTCited in: Targeted and Immune Therapy
[57]
Peters S, Salomonsen RJ, Diaz Perez I et al.. “Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study.” ESMO open (2026). PMID: 41494223 ↗
L1RCTCited in: Targeted and Immune Therapy
[58]
Li M, Pan Y, Jiang G et al.. “Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study.” ESMO open (2025). PMID: 41270700 ↗
L1RCTCited in: Targeted and Immune Therapy
[59]
O'Brien M, Paz-Ares L, Marreaud S et al.. “Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.” The Lancet. Oncology (2022). PMID: 36108662 ↗
L1RCTCited in: Targeted and Immune Therapy
[60]
Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗
L1GUIDELINECited in: Toxicity and Supportive Care, Special Populations
[61]
Wong A, Riley M, Zhao S et al.. “Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37935100 ↗
L3RETROSPECTIVE_COHORTCited in: Toxicity and Supportive Care
[62]
Khoja L, Day D, Wei-Wu Chen T et al.. “Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28945858 ↗
L2SR_COHORTCited in: Toxicity and Supportive Care
[63]
Aupérin A, Le Péchoux C, Pignon JP et al.. “Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16500915 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[64]
Novello S, Torri V, Grohe C et al.. “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34624497 ↗
L1RCTCited in: Toxicity and Supportive Care
[65]
Aupérin A, Le Péchoux C, Rolland E et al.. “Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20351327 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[66]
Hastings K, Yu HA, Wei W et al.. “EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31086949 ↗
L3RETROSPECTIVE_COHORTCited in: Toxicity and Supportive Care
[67]
Herbst RS, Wu YL, John T et al.. “Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36720083 ↗
L1RCTCited in: Toxicity and Supportive Care
[68]
Borghaei H, Gettinger S, Vokes EE et al.. “Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33449799 ↗
L1RCTCited in: Toxicity and Supportive Care
[69]
Parisi C, Mahjoubi L, Gazzah A et al.. “TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).” Cancer treatment reviews (2023). PMID: 37230055 ↗
L2SR_COHORTCited in: Toxicity and Supportive Care
[70]
Hussaini S, Chehade R, Boldt RG et al.. “Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 33302134 ↗
L4SR_COHORTCited in: Toxicity and Supportive Care
[71]
Aburaki R, Fujiwara Y, Chida K et al.. “Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: A systematic review and meta-analysis.” Cancer treatment reviews (2024). PMID: 39369455 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[72]
Hoffner B, Leighl NB, Davies M. “Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.” Cancer treatment reviews (2020). PMID: 32078962 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[73]
Rousseau A, Parisi C, Barlesi F. “Anti-TIGIT therapies for solid tumors: a systematic review.” ESMO open (2023). PMID: 36933320 ↗
L4SR_COHORTCited in: Toxicity and Supportive Care
[74]
Ulas EB, Dickhoff C, Schneiders FL et al.. “Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.” ESMO open (2021). PMID: 34479033 ↗
L2SR_COHORTCited in: Toxicity and Supportive Care
[75]
Siciliano MA, Caridà G, Ciliberto D et al.. “Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.” ESMO open (2022). PMID: 35427835 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[76]
Dafni U, Soo RA, Peters S et al.. “Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.” ESMO open (2022). PMID: 35696746 ↗
L1SR_MA_RCTCited in: Toxicity and Supportive Care
[77]
Shah NJ, Cook MR, Wu T et al.. “The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35830888 ↗
L4PROSPECTIVE_COHORTCited in: Special Populations
[78]
Singh N, Temin S, Baker S et al.. “Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35816666 ↗
L1GUIDELINECited in: Special Populations
[79]
Singh N, Temin S, Baker S et al.. “Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35816668 ↗
L1GUIDELINECited in: Special Populations
[80]
Goyal G, Enogela EM, Burkholder GA et al.. “Burden of Chronic Health Conditions Among People With HIV and Common Non-AIDS-Defining Cancers.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 40490015 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations
[81]
Lee M, Liu J, Miao E et al.. “Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 38081123 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations
[82]
Bagley SJ, Talento S, Mitra N et al.. “Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31085759 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations
[83]
Qin A, Zhao S, Miah A et al.. “Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33878726 ↗
L3RETROSPECTIVE_COHORTCited in: Special Populations
[84]
Gerber DE, Horn L, Boyer M et al.. “Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29767677 ↗
L1RCTCited in: Special Populations
[85]
Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗
L1SR_MA_RCTCited in: Special Populations
[86]
McCulloch M, See C, Shu XJ et al.. “Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16421421 ↗
L1SR_MA_RCTCited in: Special Populations
[87]
Patel JD, Socinski MA, Garon EB et al.. “PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145346 ↗
L1RCTCited in: Special Populations
[88]
Scagliotti GV, Parikh P, von Pawel J et al.. “Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37146426 ↗
L1RCTCited in: Special Populations
[89]
Landré T, Karaboué A, Buchwald ZS et al.. “Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.” ESMO open (2024). PMID: 38232612 ↗
L1SR_MA_RCTCited in: Special Populations
[90]
Reale ML, Passiglia F, Cappuzzo F et al.. “MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.” ESMO open (2024). PMID: 39214048 ↗
L4PROSPECTIVE_COHORTCited in: Special Populations
[91]
Yoshimura A, Takeda T, Tanimura K et al.. “Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study.” ESMO open (2025). PMID: 41270701 ↗
L2PROSPECTIVE_COHORTCited in: Special Populations
[92]
Chang JY, Mehran RJ, Feng L et al.. “Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery.” The Lancet. Oncology (2021). PMID: 34529930 ↗
L4PROSPECTIVE_COHORTCited in: Special Populations